Cargando…
Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection
Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s).
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906998/ https://www.ncbi.nlm.nih.gov/pubmed/36774551 http://dx.doi.org/10.1016/j.celrep.2023.112075 |
_version_ | 1784884083308888064 |
---|---|
author | Zhu, Ka-Li Jiang, Xiao-Lin Zhan, Bing-Dong Wang, Xue-Jun Xia, Xian Cao, Guo-Ping Sun, Wen-Kui Huang, Peng-Xiang Zhang, Jin-Zhong Gao, Yu-Ling Dai, Er-Hei Gao, Hui-Xia Ma, Mai-Juan |
author_facet | Zhu, Ka-Li Jiang, Xiao-Lin Zhan, Bing-Dong Wang, Xue-Jun Xia, Xian Cao, Guo-Ping Sun, Wen-Kui Huang, Peng-Xiang Zhang, Jin-Zhong Gao, Yu-Ling Dai, Er-Hei Gao, Hui-Xia Ma, Mai-Juan |
author_sort | Zhu, Ka-Li |
collection | PubMed |
description | Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4–6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants. |
format | Online Article Text |
id | pubmed-9906998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Author(s). |
record_format | MEDLINE/PubMed |
spelling | pubmed-99069982023-02-08 Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection Zhu, Ka-Li Jiang, Xiao-Lin Zhan, Bing-Dong Wang, Xue-Jun Xia, Xian Cao, Guo-Ping Sun, Wen-Kui Huang, Peng-Xiang Zhang, Jin-Zhong Gao, Yu-Ling Dai, Er-Hei Gao, Hui-Xia Ma, Mai-Juan Cell Rep Report Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4–6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants. The Author(s). 2023-02-28 2023-01-27 /pmc/articles/PMC9906998/ /pubmed/36774551 http://dx.doi.org/10.1016/j.celrep.2023.112075 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Report Zhu, Ka-Li Jiang, Xiao-Lin Zhan, Bing-Dong Wang, Xue-Jun Xia, Xian Cao, Guo-Ping Sun, Wen-Kui Huang, Peng-Xiang Zhang, Jin-Zhong Gao, Yu-Ling Dai, Er-Hei Gao, Hui-Xia Ma, Mai-Juan Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection |
title | Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection |
title_full | Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection |
title_fullStr | Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection |
title_full_unstemmed | Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection |
title_short | Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection |
title_sort | durability of neutralization against omicron subvariants after vaccination and breakthrough infection |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906998/ https://www.ncbi.nlm.nih.gov/pubmed/36774551 http://dx.doi.org/10.1016/j.celrep.2023.112075 |
work_keys_str_mv | AT zhukali durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT jiangxiaolin durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT zhanbingdong durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT wangxuejun durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT xiaxian durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT caoguoping durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT sunwenkui durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT huangpengxiang durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT zhangjinzhong durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT gaoyuling durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT daierhei durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT gaohuixia durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection AT mamaijuan durabilityofneutralizationagainstomicronsubvariantsaftervaccinationandbreakthroughinfection |